

The Association between Thyroid Hormones and Lipid Profile in Patients with Primary Hyperthyroidism

Ferdos A. Alterihy


Khawla A. shemran*

Abdulsamie H. Alta'ee*

Shahlaa K.A. Jabuk*

College of Medicine, Al-Qadisia University, Aldewania, Iraq.

*College Of Medicine, University of Babylon, Hilla, Iraq.



Abstract

Background: Thyroid hormones are important at cellular level, affecting nearly every type of tissue in the body.

Objectives: The present study was carried out to determine whether thyroid hormones affect lipid profile in patients with hyperthyroidism.

Materials and Methods: This study was carried out on 22 hyperthyroid patients (11 men and 11 women), with mean age 48.5 ± 13.1 years and 24 apparently healthy control (12 men and 12 women), with mean age 49.5 ± 11.4 years). Serum levels of, thyroid stimulated hormone TSH, thyroxine (T4) and triiodothyronine (T3) were measured by ELISA technique, and total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and Triglyceride (TG) were measured spectrophotometrically, while low-density lipoprotein cholesterol (LDL-C) and very low-density lipoprotein cholesterol (VLDL-C) were calculated.

Results: Thyroid stimulated hormone TSH, lipids and lipoproteins (TC, TG, HDL-C, LDL-C, VLDL-C) levels of patients were significantly lower than those of the control group ($p < 0.05$). And there were significant increases in serum thyroid hormones T4, T3 values ($p < 0.05$).

Conclusion: Hyperthyroidism is associated with decrease levels of lipoprotein, caused by increased hepatic uptake due to an enhanced affinity for the LDL receptor, and regulatory protein of TG (ApoAV).

الترابط بين هرمونات الغدة الدرقية ومعالم الدهون في مرضى فرط الغدة الدرقية الابتدائي

الخلاصة

الخلفية: هرمونات الغدة الدرقية مهمة على المستوى الخلوي وتؤثر تقريبا على كل أنواع الأنسجة في الجسم.

الأهداف: أجريت الدراسة الحالية لتبيان فيما اذا كان هناك تأثير لهرمونات الدرقية على مستويات الدهون في المرضى المصابين بفرط الغدة الدرقية.

المواد والطرق: أجريت الدراسة على ٢٢ مريضا مصابا بفرط الغدة الدرقية (١١ رجل و ١١ امراه ، بمتوسط عمر 48.5 ± 13.1 سنة) و ٢٤ شخص سليم ظاهريا (١٢ رجل و ١٢ امرأة) بمتوسط عمر 49.5 ± 11.4 سنة). تم تقدير مستويات هرمون TSH ، الثايروكسين (T4) ، الثايرونين ثلاثي اليود (T3) بتقنية الالايزا ، والكوليسترول الكلي (TC) ، وكوليسترول البروتين اأدهني عالي الكثافة (HDL-C) ، والكسيرات الثلاثية (TG) بطرق طيفية بينما تم حساب كوليسترول البروتين اأدهني واطي الكثافة (LDL-C) وكوليسترول البروتين اأدهني منخفض الكثافة جدا (VLDL-C) بطرق حسابية.

النتائج : وجد إن مستويات هرمون TSH والكوليسترول الكلي (TC) والكسيرات الثلاثية (TG) وكوليسترول كل من البروتين اأدهني عالي و واطي ومنخفض الكثافة جدا (HDL-C ، LDL-C ، VLDL-C) كانت واطئة جدا وبشكل معنوي مقارنة بمجموعة السيطرة كما لوحظ زيادة معنوية ($P > 0.05$) في مستويات هرمونات الدرقية (T3) و (T4).

الاستنتاج: يرتبط فرط الغدة الدرقية مع النقصان في مستويات البروتينات الدهنية ، بسبب زيادة أخذها من قبل الكبد والذي يعزى إلى زيادة الألفة لمستقبلات (LDL-C) والبروتين المنظم للكسيرات الثلاثية (TG) المسمى Apo AV.

Introduction

Thyroid disease, namely hypothyroidism and hyperthyroidism, constitutes the most common endocrine abnormality in recent years, diagnosed either in subclinical or clinical form. According to the 6-year duration (National Health and Nutrition Examination Survey III (NHANES) III Study 1988-1994, the prevalence of hyperthyroidism 1.3% (0.5% clinical and 0.7% subclinical), in population aged at least 12 years, showing an age and sex dependence [1].

Thyroid disease is associated with various metabolic abnormalities, due to the effects of thyroid hormones on nearly all major metabolic pathways. Thyroid hormones regulate the basal energy expenditure through their effect on protein, carbohydrate, and lipid metabolism. This might be a direct effect or an indirect effect by modification of other regulatory hormones such as insulin or catecholamine [2]. Dyslipidemia is a common metabolic abnormality in patients with thyroid disease, either in the overt or subclinical forms of the disease, and constitutes the end result of the effect of thyroid hormones in all aspects of lipid metabolism leading to various quantitative and/or qualitative changes of triglycerides, phospholipids, cholesterol, and other lipoproteins [3].

In thyroid disease, dyslipidemia and the coexisting metabolic abnormalities, in combination with the thyroid hormone-induced hemodynamic alterations, explain the high risk for cardiovascular disease [4- 6].

It is well established that overt hyperthyroidism induces a hyperdynamic cardiovascular state (high cardiac output with low systemic vascular resistance), which is associated with a faster heart rate, enhanced left ventricular systolic and diastolic function, and increased prevalence of supraventricular tachyarrhythmia's [7].

Although thyroid hormones play an important role in cardiovascular hemodynamics, the association between elevated thyroid hormones and low grade inflammation is still unclear [8].

Thyroid gland function regulates a wide range of metabolic events. Thyroid gland function significantly affects lipoprotein metabolism and as a result the cardiovascular disease (CVD) risk [9, 10]. In fact, even within the normal range of thyroid-stimulating hormone (TSH) values, a gradual elevations in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) and a linear depletion in high-density lipoprotein cholesterol (HDL-C) levels has been observed with increasing TSH [11,12].

In healthy people, the thyroid makes just the right amounts of two hormones, thyroxine (T4) and triiodothyronine (T3), which have important actions throughout the body. These hormones regulate many aspects of our metabolism, eventually affecting how many calories we burn, how warm we feel, and how much we weigh. These hormones also have direct effects on most organs, including the heart, which beats faster and harder under the influence of thyroid hormones. Essentially, all cells in the body will respond to increases in thyroid hormone with an increase in the rate at which they conduct their business [13].

Determination of the serum TSH is the most sensitive way to screen for hyperthyroidism. A marked improvement in the sensitivity of the TSH assay makes it possible to diagnose hyperthyroidism solely on the basis of an absence of detectable TSH. Most patients with overt hyperthyroidism have TSH levels of less than 0.05 μ U/mL. As long as the hypothalamic-pituitary axis is intact, an absence of detectable TSH represents the appropriate response to too much

circulating thyroid hormone. Undetectable TSH by second- or third-generation assay is diagnostic of hyperthyroidism. A normal TSH level virtually rules out hyperthyroidism, unless a rare TSH-secreting pituitary adenoma is present [14].

Materials and Methods

This study was carried out on 22 hyperthyroid subjects (11 men and 11 women) (mean age 48.5 ± 13.1 years) whom were collected from Aldewania Teaching Hospital in Aldewania city between 2009-2010. The diagnosis of hyperthyroidism was made on the basis of clinical examination, elevated circulating levels of (T4) or (T3) and suppressed TSH levels. The causes of hyperthyroidism were Graves disease in all of the patients.

The control group includes 24 apparently healthy individuals (12 men and 12 women) (mean age 49.5 ± 11.4 years), after having been asked about their health.

Fasting blood samples to determine the thyroid function TSH, T4, T3, TC, TG and HDL-C were

drawn at beginning of the study and LDL-C and VLDL-C was calculated.

Levels of total cholesterol, triglyceride and HDL-C were measured by Biomagreb kit. While the TSH, T4 and T3 were measured by ELISA Kit from Monobind company.

Statistical analysis

This study is a case-control study. Student's t-test has been used to determine the significant difference between two groups, where p values of less than 0.05 is considered significant.

Results

The concentrations of serum thyroid hormones (T3 and T4), lipids (cholesterol and triglyceride), lipoproteins (HDL-cholesterol, LDL-cholesterol and VLDL-cholesterol) and TSH in patient with hyperthyroidism are presented in Table 1. There were significant increases ($p < 0.05$) in serum thyroid hormones (T4 ,T3) values, and also the table show as there were a significant decreases in TSH, lipids and lipoproteins (TC, TG , HDL-C, LDL-C, VLDL-C) values ($p < 0.05$) in patient group than control group.

Table 1 Lipid profile and thyroid hormones values in control and patients.

Parameter	Control	Patient	P-Value
	Mean $\pm$ SD	Mean $\pm$ SD	
TSH (μ U/ml)	1.24 $\pm$ 0.5	0.5 $\pm$ 0.4	0.00
T4 (μ g/dl)	6.87 $\pm$ 1.8	9.65 $\pm$ 3.76	0.00
T3 (ng/ml)	0.49 $\pm$ 0.211	2.1 $\pm$ 0.87	0.00
T4/T3 ratio	14.02 $\pm$ 8.53	4.59 $\pm$ 4.32	0.00
TC (mg/dl)	228.5 $\pm$ 28	200 $\pm$ 53.9	0.03
TG (mg/dl)	174.5 $\pm$ 28.4	157.5 $\pm$ 28.8	0.02
HDL-C (mg/dl)	41.8 $\pm$ 0.7	32 $\pm$ 5.8	0.04
LDL-C (mg/dl)	159 $\pm$ 28	104.5 $\pm$ 52.1	0.00
VLDL-C (mg/dl)	34.9 $\pm$ 5.68	31.5 $\pm$ 5.76	0.02

Discussion

Thyroid function regulates a wide array of metabolic parameters. Thyroid function significantly affects lipoprotein metabolism as well as some cardiovascular disease (CVD) risk factors [9][10]. Indeed, in the case of high level range of thyroid-stimulating hormone (TSH) values, there are a linear increase in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) and there are a linear decrease in high-density lipoprotein cholesterol (HDL-C) and this agree with our result [11].

Thyroid hormones induce the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is the first step in cholesterol biosynthesis. Moreover, triiodothyronine (T3) upregulates LDL receptors by controlling the LDL receptor gene activation. This T3-mediated gene activation is done by the direct binding of T3 to specific thyroid hormone responsive elements (TREs) [15]. Furthermore, T3 controls the sterol regulatory element-binding protein-2 (SREBP-2), which in turn regulates LDL receptor's gene expression [16]. T3 has also been associated with protecting LDL from oxidation [17]. This may explain the results of present study.

Thyroid hormones can influence HDL metabolism by increasing cholesteryl ester transfer protein (CETP) activity, which exchanges cholesteryl esters from HDL2 to the very low density lipoproteins (VLDL) and TGs to the opposite direction [18]. In addition, thyroid hormones stimulate the lipoprotein lipase (LPL), which catabolizes the TG-rich lipoproteins, and the hepatic lipase (HL), which hydrolyzes HDL2 to HDL3 and contributes to the conversion of intermediate-density lipoproteins

(IDL) to LDL and in turn LDL to small dense LDL (sdLDL) [19][20]. Another effect of T3 is the up-regulation of apolipoprotein AV (ApoAV), which plays a major role in TG regulation [21]. Indeed, increased levels of ApoAV have been associated with decreased levels of TGs [22]. Proposed mechanisms for this effect include the decrease of hepatic VLDL-TG production and the increase of plasma LPL levels and activity, resulting in increase of lipoprotein generation due to enhanced LPL-mediated lipolysis of VLDL-TG [22]. Moreover, a greater clearance of lipoprotein, caused by increased hepatic uptake due to an enhanced affinity for the LDL receptor, has also been ascribed to ApoAV [22]. This might be explain the decrease in VLDL-C and TG in the present study

Hyperthyroidism has profound effects on cardiovascular system, including reduced systemic vascular resistance due to relaxation of vascular smooth muscle cells, enhanced heart rate and cardiac output due to increase in cardiac diastolic relaxation, contractility and heart rate[23]. Hyperthyroidism is characterised by reduced serum TSH levels despite increased thyroxine (T4) and triiodothyronine (T3) levels.

Altered lipid profile is a well-known manifestation of thyroid dysfunction. Both plasma LDL-C and HDL-C increase in hypothyroidism and decrease in hyperthyroidism [24-28]. Also, this agree with our results.

It is well-known that thyroid dysfunctions have profound effects on lipoprotein metabolism [29]. The main cause of the differences in total cholesterol concentrations is the alterations of LDL-C levels. In hyperthyroidism, the increase in LDL receptor mRNA leads to an increase in activity and number of LDL receptors [30]. This in turn, leads to a decrease

in concentrations of LDL-C and TC levels. In another study, it is reported that hyperthyroidism induces a decrease in serum cholesterol [31], and this is agree with result of present study.

In hyperthyroid cases a decrease in HDL-C levels are also observed [32]. This decrease suggested being due to increased hepatic triglyceride lipase activity. Through the effects of thyroid hormones, hepatic lipase, a decrease, in HDL2/HDL3 is reported. The most prominent alteration in HDL-C is due to the changes in HDL2 sub-fraction [29]. These findings are consistent with the literature[33].

It is important to achieve an euthyroid state as soon as possible in hyperthyroid patients. However, normalization of hyperthyroid hormones are frequently associated with the elevation of proatherogenic lipids[34].

In conclusion, hyperthyroidism is associated with decrease levels of lipoprotein, caused by increased hepatic uptake due to an enhanced affinity for the LDL receptor, and regulatory protein of TG.

References

1. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III) Journal of Clinical Endocrinology and Metabolism. 2002; 87(2):489–499.
2. Kim B. Thyroid hormone as a determinant of energy expenditure and the basal metabolic rate. Thyroid. 2008; 18 (2):141–144.
3. Zhu X, Cheng SY. New insights into regulation of lipid metabolism by thyroid hormone. Current Opinion in Endocrinology, Diabetes and Obesity. 2010;17(5):408–413.
4. Biondi B, Klein I. Hypothyroidism as a risk factor for cardiovascular disease. Endocrine. 2004;24(1):1–13.
5. Fazio S, Palmieri EA, Lombardi G, Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Progress in Hormone Research. 2004;59:31–50.
- 6- Melpomeni Peppas, Grigoriadis Betsi, , George Dimitriadis. Lipid Abnormalities and Cardiometabolic Risk in Patients with Overt and Subclinical Thyroid Disease. J Lipids. 2011; July 18
- 7- Merce J, Ferras S, Oltra C, Sanz E, Vendrell J, Simon I, Camprubi M, Bardaji A, Rida C. Cardiovascular abnormalities in hyperthyroidism: a prospective Doppler echocardiographic study. Am J Med (2005) 118: 126-131,.
- 8- Sibel Güldiken. Muzaffer Demir. Ender Arıkan. Armağan Tuğrul. The Level of Serum High Sensitive C-Reactive Protein in Women with Hyperthyroidism. Turkish Journal of Endocrinology and Metabolism, (2005) 3 : 85-88.
- 9- Duntas LH. Thyroid disease and lipids. Thyroid 2002; 12: 287-93.
- 10- Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160: 526- 34.
- 11- Asvold BO, Vatten LJ, Nilsen TI, Bjoro T. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study. Eur J Endocrinol 2007; 156: 181-6.
- 12 - C.V. Rizos, M.S. Elisaf and E.N. Liberopoulos. Effects of Thyroid Dysfunction on Lipid Profile. The Open Cardiovascular Medicine Journal, 2011, 5, 76-84
13. Engler H, Riesen WF. Effect of thyroid function on concentrations of lipoprotein(a). Clin Chem 1993; 39: 2466-2469.

- 14- David M. Slovik., Primary Care Medicine: Office Evaluation and Management of the Adult Patient,6th Edition, 2009 Lippincott Williams & Wilkins, P(789 -798).
- 15- Bakker O, Hudig F, Meijssen S, Wiersinga WM. Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene. *Biochem Biophys Res Commun.* 1998;249:517–21.
- 16- Shin DJ, Osborne TF. Thyroid hormone regulation and cholesterol metabolism are connected through Sterol Regulatory Element-Binding Protein-2 (SREBP-2) *J Biol Chem.* 2003;278:34114–8.
- 17- Faure P, Oziol L, Artur Y, Chomard P. Thyroid hormone (T3) and its acetic derivative (TA3) protect low-density lipoproteins from oxidation by different mechanisms. *Biochimie.* 2004; 86:411–8.
- 18- Lagrost L. Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studies. *Biochim Biophys Acta.* 1994; 1215: 209–36.
- 19- Kuusi T, Saarinen P, Nikkila EA. Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein2 in man. *Atherosclerosis.* 1980;36:589–93.
- 20- Santamarina-Fojo S, Gonzalez-Navarro H, Freeman L, Wagner E, Nong Z. Hepatic lipase, lipoprotein metabolism, and atherogenesis. *Arterioscler Thromb Vasc Biol.* 2004;24:1750–4.
- 21- Prieur X, Huby T, Coste H, Schaap FG, Chapman MJ, Rodriguez JC. Thyroid hormone regulates the hypotriglyceridemic gene APOA5. *J Biol Chem.* 2005;280:27533–43.
- 22- Rensen PC, van Dijk KW, Havekes LM. Apolipoprotein AV: low concentration, high impact. *Arterioscler Thromb Vasc Biol.* 2005;25:2445–7.
- 23- Faber J, Wiinberg N, Schifter S, Mehlsen J. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. *Eur J Endocrinol* 2001;145:391-396.
- 24- Diekman MJ, Anghelescu N, Endert E, Bakker O, Wiersinga WM. Changes in plasma low-density lipoprotein (LDL) - and high-density lipoprotein cholesterol in hypo- and hyperthyroid patients are related to changes in free thyroxine, not to polymorphisms in LDL receptor or cholesterol ester transfer protein genes. *J Clin Endocrinol Metab* 2000;85:1857-1862.
- 25- Wonn-Young L, Jung-Yul S, Eun-Jung R, Jeong-Sik P, Ki-Chul S, Sun-Woo K. Plasma CRP, Apolipoprotein A-1, Apolipoprotein B and Lp (a) levels according to thyroid function status. *Arch Med Res* 2004;35:540-545.
- 26- Chadarevian R, Bruckert E, Giral P, Turpin G. Relationship between thyroid hormones and fibrinogen levels. *Blood Coagul Fibrinolysis* 1999;10:481-486.
- 27- Diekman MJ, van der Put NM, Blom HJ, Tijssen JG, Wiersinga WM. Determinants of changes in plasma homocysteine in hyperthyroidism and hypothyroidism. *Clin Endocrinol (Oxf)* 2001;54:197-204.
- 28- Matsubara M, Yoshizawa T, Morioka T, Katayose S. Serum leptin and lipids in patients with thyroid dysfunction. *J. Ath-eroscler, Thromb(2000);7:50-54.*
- 29- Ponsin G, Vialle-Valentin C, Berthezene F. Alterations of high density lipoproteins induced by thyroid hormones in man and rat. *Adv Exp Med Biol* 1991;285:147-154.
30. Ruggiero FM, Cafagna F, Quagliariello E. Exchange of free cholesterol between plasma and erythrocytes from hyperthyroid and hypothyroid rats in vitro. *Lipids* 1990;25:529-533.

31- Parle JV, Franklyn JA, Cross KW, Jones SR, Sheppard MC. Circulating lipids and minor abnormalities of thyroid function. Clin. Endocrinol 1992; 37: 411-414.

32. Staels B, Van Tol A, Chan L, Will H, Verhoeven G, Auwerx J. Alterations in thyroid status modulate apolipoprotein, hepatic triglyceride lipase, and low density lipoprotein receptor in rats. Endocrinology 1990;127:1144-1152.

33. Hoch FL. Lipids and thyroid hormones. Prog Lipid Res 1988;27:199-270.

34- Emine Sütken¹, Aysen Akalın², Filiz Özdemir³, Ömer Çolak. Lipid profile and levels of homocysteine, leptin, fibrinogen and C-reactive protein in hyperthyroid patients before and after treatment. Dicle Med J Cilt / Vol 37, No 1, 1-7.